You are testing whether the medications, side effects, costs, adherence burden (how many pills you cumulatively have to pop each day), and long-term medicalisation are justified by the likely absolute benefit
In other words, BPC 157 may support the conditions that allow hypertrophy training to continue, but it should not be framed as a direct muscle-growth peptide
If any symptoms persist or worsen, or you notice any other symptoms, please call your doctor
Athira Pharma (formerly M3 Biotechnology), the WSU spinout founded to commercialize Dihexa-derivative compounds, paid approximately $4 million in a False Claims Act settlement in January 2025 after a whistleblower exposed concealment of the research misconduct from federal grant agencies, and approximately $10 million in a separate class-action settlement to investors
Narcolepsy evidence is inadequate
By activating GLP-1 receptors, semaglutide suppresses appetite, reduces hunger cravings, and lowers calorie intake